Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802464 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
A Phase 2 study of Herpes Zoster, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 410
- Enrollment target
- 12
- Study locations
NCT00802464: Completed Phase 2 study of Herpes Zoster, sponsored by GlaxoSmithKline.
NCT00802464 is a Phase 2 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 410 participants, below the 2,148-participant average among 16 other Herpes Zoster trials with a reported enrollment target (81% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802464, a Phase 2 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 410 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.
Primary Outcome
The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Herpes zoster vaccine GSK1437173A
Study Locations (12)
Other
- GSK Investigational Site - Hradec Králové
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Mahadahonda( Madrid
- GSK Investigational Site - Marid
Arizona
- GSK Investigational Site - Phoenix
Florida
- GSK Investigational Site - Pembroke Pines
Nevada
- GSK Investigational Site - Las Vegas
New Jersey
- GSK Investigational Site - Edison
North Carolina
- GSK Investigational Site - Raleigh
Ohio
- GSK Investigational Site - Cleveland
Pennsylvania
- GSK Investigational Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2009-01-12 |
| Est. Completion | 2010-07-02 |
| Phase | Phase 2 |
What the finished NCT00802464 record still lists
NCT00802464 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 2,148-participant average among 16 other Herpes Zoster trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00802464 lists 12 locations in 8 states (Other, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT00802464 about?
NCT00802464 is a clinical study titled "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years". The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.
What is the current status of trial NCT00802464?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 410 participants. The study started on 2009-01-12. Estimated completion is 2010-07-02.
What conditions does trial NCT00802464 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT00802464?
The interventions under investigation include: Placebo (BIOLOGICAL), Herpes zoster vaccine GSK1437173A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00802464?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00802464 being conducted?
This trial has 12 study locations across Arizona, Florida, Nevada, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00802464's enrollment target sits among peer trials
410 9th of 16 higher than 8 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
-
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
COMPLETED · Phase 2
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI